- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Barry Russo Discusses Challenges of Juggling OCM and MIPS
Many oncology practices are still trying to understand the new Oncology Care Model (OCM) structure and focus on data reporting as they simultaneously prepare to adapt to the Merit-based Incentive Payment System (MIPS), said Barry Russo, CEO of The Center for Cancer & Blood Disorders.
Many oncology practices are still trying to understand the new oncology care model (OCM) structure and focus on data reporting as they simultaneously prepare to adapt to the Merit-based Incentive Payment System (MIPS), said Barry Russo, CEO of The Center for Cancer & Blood Disorders.
Transcript (slightly modified)
How is your practice collecting and using data from quality measures?
We’re still trying to understand all the nuances to it. We’re not sure we’re going to be willing or understanding the two-sided risk of the OCM product so we probably will, if we’re still as unclear about it when it comes time for MIPS, we will probably be a MIPS practice. We haven’t read through all 23 or 2500 pages of what exists out there, but conceptually, we kind of understand where they’re going with it. Our focus is to understand the data reporting and try and optimize that as much as we possibly can.
I wish OCM—because in the midst of OCM, we had to flip to a MIPS mindset—I wish outside of double-sided risk that OCM would have some, for some more reasonable period of time, have an opportunity to be an APM and not have to flip into thinking about MIPS, but it doesn’t look like that’s going to be the case for us. Unless we’re willing to take two-sided risk, which, it’s way too early for us to understand and know that yet.
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
